BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed AMGN catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:23a9610247924b6ad4ed@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:AMGN P1/P2 readout (est.): MTAPESTRY 101
DESCRIPTION:A Study of Anvumetostat in Participants With Advanced MTAP-null
  Solid Tumors (MTAPESTRY 101)\nNCT05094336 | PHASE1/PHASE2 | ACTIVE_NOT_RE
 CRUITING | sponsor: Amgen\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nTicker AMGN (confidence 0.9)\nSource: https
 ://clinicaltrials.gov/study/NCT05094336\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05094336
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ed4c88f60437e23a2078@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:AMGN P3 readout (est.): Eucalyptus
DESCRIPTION:Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pemb
 rolizumab)\nNCT06430866 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Amgen\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nTicker AMGN (confidence 0.9)\nSource: https://clinicaltrials.gov/stud
 y/NCT06430866\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06430866
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c37640b98878616f875b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:AMGN P1/P2 readout (est.): A Study of AMG 732 in Healthy Participan
 ts and Participants With Thyroid Eye Disease
DESCRIPTION:A Study of AMG 732 in Healthy Participants and Participants Wit
 h Thyroid Eye Disease\nNCT06401044 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING
  | sponsor: Amgen\nPrimary completion date (ESTIMATED)\; top-line results 
 usually follow later.\nTicker AMGN (confidence 0.9)\nSource: https://clini
 caltrials.gov/study/NCT06401044\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06401044
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d189451e8ecce656ae9c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:AMGN P3 readout (est.): MARITIME-1
DESCRIPTION:Evaluation of Maridebart Cafraglutide in Adult Participants Wit
 hout Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nNCT06858
 839 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Amgen\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nTicker AMGN (co
 nfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06858839\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06858839
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:79d51bd783a3d0ef1739@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:AMGN P3 readout (est.): MARITIME-2
DESCRIPTION:Efficacy and Safety of Maridebart Cafraglutide in Adult Partici
 pants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nNC
 T06858878 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Amgen\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nTicker AM
 GN (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06858878\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06858878
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:50ab17ca9fafc44132a3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261022
DTEND;VALUE=DATE:20261023
SUMMARY:AMGN APPROVAL: PAVBLU
DESCRIPTION:Approved 2026-10-22: PAVBLU (BLA761298 ORIG2)\nConfidence: conf
 irmed\nTicker AMGN (confidence 0.9)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761298\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761298
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:1e4415a12266799794fd@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261009
DTEND;VALUE=DATE:20261010
SUMMARY:AMGN APPROVAL: REPATHA
DESCRIPTION:Approved 2026-10-09: REPATHA (BLA125522 SUPPL47)\nConfidence: c
 onfirmed\nTicker AMGN (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125522
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:0b07b64750e66bd5b4e2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251119
DTEND;VALUE=DATE:20251120
SUMMARY:AMGN APPROVAL: IMDELLTRA
DESCRIPTION:Approved 2025-11-19: IMDELLTRA (BLA761344 SUPPL1)\nConfidence: 
 confirmed\nTicker AMGN (confidence 0.9)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761344\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761344
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
